Shares of Moderna Inc. gained 0.4% in premarket trading on Thursday after the company said it’s now signed $21 billion in advance purchase agreements for 2022 for its COVID-19 vaccine. That’s up from $19 billion in signed agreements at the end of February. Moderna has not yet signed a new purchase agreement with the U.S.; in the news release, it confirmed that discussions for 2022 and 2023 agreements are going with several countries, “including with the U.S.” Moderna’s stock is down 29.6% so far this year, while the S&P 500 has declined 6.5%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
